The aim of this examine was to guage the cleansing and floor therapy strategies within the restore of aged and contaminated yttrium oxide-stabilized tetragonal polycrystalline zirconia (Y-TZP). From a complete of 80 specimens of Y-TZP, 60 have been subjected to ageing simulation in a buccal atmosphere with degradation in an autoclave for 24 hours (127°C/1.5 bar) and contaminated with Streptococcus mutans. The surfaces have been cleaned with a triple syringe (air/water jet; n = 20) or isopropyl alcohol (n = 20), or by prophylaxis (n = 20) with pumice and water. The remaining 20 specimens comprised the management group.
All specimens have been then handled with silicatization (n = 10 per group) or adhesive (n = 10 per group) and repaired with composite resin. Analyses of shear power, failure mode, and roughness have been carried out by electron microscopy. Information have been analyzed by two-way evaluation of variance (ANOVA) and t check (α = .05). Statistical significance was set at P < .05. Two-way ANOVA was vital for ageing and floor therapies (P = .049), however was not vital for floor cleansing (P = .05). ANOVA outcomes have been statistically vital for floor therapies (P < .0001), with increased resistance for the silicatization teams. The failure mode was largely adhesive for all specimens. The roughness was not vital for ageing and management teams (P > .05). Triple-syringe and prophylaxis cleaning adopted by silicatization was probably the most environment friendly therapy for the restore of aged and contaminated Y-TZP. There may be decreased restore effectivity with the ageing of Y-TZP.
Respiratory Syncytial Virus (RSV) is the key explanation for extreme acute respiratory tract sickness in younger kids worldwide and a most important pathogen for the aged and immune-compromised folks. Within the absence of vaccines or efficient therapies, a greater characterization of the pathogenesis of RSV an infection is required. To this point, the pathophysiology of the illness and its analysis has largely relied on chest X-ray and genome detection in nasopharyngeal swabs. The event of latest imaging approaches is instrumental to additional the outline of RSV unfold, virus-host interactions and associated acute respiratory illness, on the degree of your complete lung.
Characterization of Bio-Impressed Electro-Conductive Soy Protein Movies
Protein-based conductive supplies are gaining consideration as various parts of digital units for value-added purposes. On this regard, soy protein isolate (SPI) was processed by extrusion in an effort to get hold of SPI pellets, subsequently molded into SPI movies by sizzling urgent, leading to homogeneous and clear movies, as proven by scanning electron microscopy and UV-vis spectroscopy analyses, respectively. Throughout processing, SPI denatured and refolded by means of intermolecular interactions with glycerol, inflicting a serious exposition of tryptophan residues and fluorescence emission, affecting cost distribution and electron transport properties.
Concerning electrical conductivity, the worth discovered (9.889 × 10-4 S/m) is attribute {of electrical} semiconductors, corresponding to silicon, and better than that discovered for different pure polymers. Moreover, the habits of the movies involved with water was analyzed, indicating a managed swelling and a hydrolytic floor, which is of nice relevance for cell adhesion and spreading. Actually, cytotoxicity research confirmed that the developed SPI movies have been biocompatible, based on the rules for the organic analysis of medical units. Due to this fact, these SPI movies are uniquely suited as bioelectronics as a result of they conduct each ionic and digital currents, which isn’t accessible for the standard metallic conductors.
Combining In Vivo Corneal Confocal Microscopy With Deep Studying-Based mostly Evaluation Reveals Sensory Nerve Fiber Loss in Acute Simian Immunodeficiency Virus An infection
To characterize corneal subbasal nerve plexus options of regular and simian immunodeficiency virus (SIV)-infected macaques by combining in vivo corneal confocal microscopy (IVCM) with automated assessments utilizing deep learning-based strategies personalized for macaques. IVCM photos have been collected from each female and male age-matched rhesus and pigtailed macaques housed on the Johns Hopkins College breeding colony utilizing the Heidelberg HRTIII with Rostock Corneal Module. We additionally obtained repeat IVCM photos of 12 SIV-infected animals together with preinfection and 10-day post-SIV an infection time factors. All IVCM photos have been analyzed utilizing a deep convolutional neural community structure developed particularly for macaque research.
Deep learning-based segmentation of subbasal nerves in IVCM photos from macaques demonstrated that corneal nerve fiber size and fractal dimension measurements didn’t differ between species, however pigtailed macaques had considerably increased baseline corneal nerve fiber tortuosity than rhesus macaques (P = 0.005). Neither intercourse nor age of macaques was related to variations in any of the assessed corneal subbasal nerve parameters. Within the SIV/macaque mannequin of human immunodeficiency virus, acute SIV an infection induced vital decreases in each corneal nerve fiber size and fractal dimension (P = 0.01 and P = 0.008, respectively).
The mix of IVCM and sturdy goal deep studying evaluation is a robust software to trace sensory nerve injury, enabling early detection of neuropathy. Adapting deep studying analyses to scientific corneal nerve assessments will enhance monitoring of small sensory nerve fiber injury in quite a few scientific settings together with human immunodeficiency virus.
 Copper Sulphate |
|
abx186748-5g |
Abbexa |
5 g |
EUR 226.8 |
|
|
 Nile Red |
|
60029 |
Biotium |
10MG |
EUR 150 |
|
Description: Minimum order quantity: 1 unit of 10MG |
Nile Red |
|
B8209-10 |
ApexBio |
10 mg |
EUR 129.6 |
Nile Red |
|
B8209-100 |
ApexBio |
100 mg |
EUR 170.4 |
Nile Red |
|
B8209-50 |
ApexBio |
50 mg |
EUR 150 |
Nile Red |
|
B8209-500 |
ApexBio |
500 mg |
EUR 254.4 |
 Mouse antibody for West Nile Virus Envelope |
|
3655 |
Virostat |
100 ug |
EUR 386.26 |
|
Description: This is purified Mouse monoclonal antibody against West Nile Virus Envelope for WB, ELISA. |
Mouse antibody for West Nile Virus Envelope |
|
3661 |
Virostat |
100 ug |
EUR 386.26 |
|
Description: This is purified Mouse monoclonal antibody against West Nile Virus Envelope for WB, ELISA. |
Mouse antibody for West Nile Virus Envelope |
|
3671 |
Virostat |
100 ug |
EUR 386.26 |
|
Description: This is purified Mouse monoclonal antibody against West Nile Virus Envelope for WB, ELISA. |
 DHEA Sulphate antibody |
|
20-1424 |
Fitzgerald |
100 ul |
EUR 788.4 |
|
Description: Sheep polyclonal DHEA Sulphate antibody |
) CLIA kit for Rat HSPG (Heparan Sulphate Proteoglycan) |
|
E-CL-R0336 |
Elabscience Biotech |
1 plate of 96 wells |
EUR 700.8 |
|
|
|
Description: A sandwich CLIA kit for quantitative measurement of Rat HSPG (Heparan Sulphate Proteoglycan) in samples from Serum, Plasma, Cell supernatant |
 Heparan Sulphate Proteoglycan antibody |
|
10R-8070 |
Fitzgerald |
100 ug |
EUR 489.6 |
|
Description: Rat monoclonal Heparan Sulphate Proteoglycan antibody |
 West Nile virus antibody |
|
10-1436 |
Fitzgerald |
100 ug |
EUR 489.6 |
|
Description: Mouse monoclonal West Nile virus antibody |
West Nile virus antibody |
|
10-1437 |
Fitzgerald |
100 ug |
EUR 489.6 |
|
Description: Mouse monoclonal West Nile virus antibody |
 ECOS Blue (XL1-Blue |
|
FYE107-10VL |
Yeastern Biotech |
100 µl x 10 vials |
Ask for price |
ECOS Blue (XL1-Blue |
|
FYE107-80VL |
Yeastern Biotech |
100 µl x 10 vials |
Ask for price |
ECOS Blue (XL1-Blue |
|
FYE108-10VL |
Yeastern Biotech |
100 µl x 10 vials |
Ask for price |
ECOS Blue (XL1-Blue |
|
FYE108-80VL |
Yeastern Biotech |
100 µl x 10 vials |
Ask for price |
ECOS Blue (XL1-Blue |
|
FYE109-10VL |
Yeastern Biotech |
100 µl x 10 vials |
Ask for price |
ECOS Blue (XL1-Blue |
|
FYE109-80VL |
Yeastern Biotech |
100 µl x 10 vials |
Ask for price |
 Positive control tissue section for each individua |
|
Control-Slides-for-each-antibody |
Innovex |
Set of 25 |
EUR 355 |
|
Description: Positive control tissue section for each individual antibody; Based on availability; INQUIRE |
 Antibody) Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNCA0315-250 |
Biotium |
250uL |
EUR 459.6 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), APC conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNCAP0315-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNCAP0315-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC610315-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF660R conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC610315-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF660R conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC680315-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF568 conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC680315-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF568 conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNCR0315-250 |
Biotium |
250uL |
EUR 459.6 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), RPE conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNUB0315-100 |
Biotium |
100uL |
EUR 250.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), Concentration: 0.2mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNUB0315-500 |
Biotium |
500uL |
EUR 549.6 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), Concentration: 0.2mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC430315-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF543 conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC430315-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF543 conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC470315-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF647 conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC470315-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF647 conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC400315-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF640R conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC400315-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF640R conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC880315-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF488A conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC880315-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF488A conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC810315-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF680R conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC810315-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF680R conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNCP0315-250 |
Biotium |
250uL |
EUR 459.6 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), PerCP conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNUM0315-50 |
Biotium |
50uL |
EUR 474 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), 1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC050315-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF405M conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC050315-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF405M conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC700315-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF770 conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC700315-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF770 conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC800315-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF680 conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC800315-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF680 conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNCB0315-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), Biotin conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNCB0315-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), Biotin conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC940315-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF594 conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC940315-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF594 conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC550315-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF555 conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC550315-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF555 conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNCH0315-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNCH0315-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC040315-100 |
Biotium |
100uL |
EUR 238.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF405S conjugate, Concentration: 0.1mg/mL |
Heparan Sulphate Proteoglycan(A7L6) Antibody |
|
BNC040315-500 |
Biotium |
500uL |
EUR 652.8 |
|
Description: Primary antibody against Heparan Sulphate Proteoglycan(A7L6), CF405S conjugate, Concentration: 0.1mg/mL |
 Recombinant West Nile Envelope Virus |
|
7-07960 |
CHI Scientific |
100µg |
Ask for price |
Recombinant West Nile Envelope Virus |
|
7-07961 |
CHI Scientific |
500µg |
Ask for price |
Recombinant West Nile Envelope Virus |
|
7-07962 |
CHI Scientific |
1000µg |
Ask for price |
 West Nile Virus Matrix Antibody |
|
24278-100ul |
SAB |
100ul |
EUR 468 |
West Nile Virus Matrix Antibody |
|
24279-100ul |
SAB |
100ul |
EUR 468 |
 West Nile Virus Core Antibody |
|
24281-100ul |
SAB |
100ul |
EUR 468 |
 West Nile Virus Envelope Antibody |
|
24282-100ul |
SAB |
100ul |
EUR 468 |
West Nile Virus Envelope Antibody |
|
24283-100ul |
SAB |
100ul |
EUR 468 |
West Nile Virus Envelope Antibody |
|
24284-100ul |
SAB |
100ul |
EUR 468 |
West Nile Virus Matrix Antibody |
|
3429-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
|
|
Description: West Nile Virus Matrix Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins. However, when the viruses are inside of infected cells, the matrix protein exists in its "pre-M" form as a heterodimer with the envelope proteins. Cleavage of the "pre-M" protein to its mature form occurs during release of the virus; this cleavage leas to the dissociation of the heterodimers. The WNV receptor has recently been identified as alpha v beta 3 integrin. |
West Nile Virus Matrix Antibody |
|
3429-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
|
|
Description: West Nile Virus Matrix Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins. However, when the viruses are inside of infected cells, the matrix protein exists in its "pre-M" form as a heterodimer with the envelope proteins. Cleavage of the "pre-M" protein to its mature form occurs during release of the virus; this cleavage leas to the dissociation of the heterodimers. The WNV receptor has recently been identified as alpha v beta 3 integrin. |
 West Nile Virus Matrix Peptide |
|
3429P |
ProSci |
0.05 mg |
EUR 197.7 |
|
Description: (IN) West Nile Virus Matrix peptide |
West Nile Virus Matrix Antibody |
|
3431-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
|
|
Description: West Nile Virus Matrix Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins. However, when the viruses are inside of infected cells, the matrix protein exists in its "pre-M" form as a heterodimer with the envelope proteins. Cleavage of the "pre-M" protein to its mature form occurs during release of the virus; this cleavage leas to the dissociation of the heterodimers. The WNV receptor has recently been identified as alpha v beta 3 integrin. |
West Nile Virus Matrix Antibody |
|
3431-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
|
|
Description: West Nile Virus Matrix Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins. However, when the viruses are inside of infected cells, the matrix protein exists in its "pre-M" form as a heterodimer with the envelope proteins. Cleavage of the "pre-M" protein to its mature form occurs during release of the virus; this cleavage leas to the dissociation of the heterodimers. The WNV receptor has recently been identified as alpha v beta 3 integrin. |
West Nile Virus Matrix Peptide |
|
3431P |
ProSci |
0.05 mg |
EUR 197.7 |
|
Description: (CT) West Nile Virus Matrix peptide |
West Nile Virus Core Antibody |
|
3435-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
|
|
Description: West Nile Virus Core Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins which play a major role for WNV entry into target cells. The viral core protein is thought to contribute to the WNV-associated inflammation via apoptosis induced though the caspase-9 pathway as delivery of core gene delivery into the striatum of mouse brain and skeletal muscle resulted in cell death and inflammation. |
West Nile Virus Core Antibody |
|
3435-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
|
|
Description: West Nile Virus Core Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins which play a major role for WNV entry into target cells. The viral core protein is thought to contribute to the WNV-associated inflammation via apoptosis induced though the caspase-9 pathway as delivery of core gene delivery into the striatum of mouse brain and skeletal muscle resulted in cell death and inflammation. |
 West Nile Virus Core Peptide |
|
3435P |
ProSci |
0.05 mg |
EUR 197.7 |
|
Description: (CT) West Nile Virus Core peptide |
West Nile Virus Envelope Antibody |
|
3437-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
|
|
Description: West Nile Virus Envelope Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins. While the viral core protein is thought to contribute to the WNV-associated inflammation via apoptosis induced though the caspase-9 pathway, the highly glycosylated envelope protein plays a major role for WNV entry into target cells as this entry can be inhibited by using a recombinant domain III from the envelope glycoprotein. The WNV receptor has recently been identified as alpha v beta 3 integrin. |
West Nile Virus Envelope Antibody |
|
3437-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
|
|
Description: West Nile Virus Envelope Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins. While the viral core protein is thought to contribute to the WNV-associated inflammation via apoptosis induced though the caspase-9 pathway, the highly glycosylated envelope protein plays a major role for WNV entry into target cells as this entry can be inhibited by using a recombinant domain III from the envelope glycoprotein. The WNV receptor has recently been identified as alpha v beta 3 integrin. |
 West Nile Virus Envelope Peptide |
|
3437P |
ProSci |
0.05 mg |
EUR 197.7 |
|
Description: (IN) West Nile Virus Envelope peptide |
West Nile Virus Envelope Antibody |
|
3439-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
|
|
Description: West Nile Virus Envelope Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins. While the viral core protein is thought to contribute to the WNV-associated inflammation via apoptosis induced though the caspase-9 pathway, the highly glycosylated envelope protein plays a major role for WNV entry into target cells as this entry can be inhibited by using a recombinant domain III from the envelope glycoprotein. The WNV receptor has recently been identified as alpha v beta 3 integrin. |
West Nile Virus Envelope Antibody |
|
3439-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
|
|
Description: West Nile Virus Envelope Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins. While the viral core protein is thought to contribute to the WNV-associated inflammation via apoptosis induced though the caspase-9 pathway, the highly glycosylated envelope protein plays a major role for WNV entry into target cells as this entry can be inhibited by using a recombinant domain III from the envelope glycoprotein. The WNV receptor has recently been identified as alpha v beta 3 integrin. |
West Nile Virus Envelope Peptide |
|
3439P |
ProSci |
0.05 mg |
EUR 197.7 |
|
Description: (NT) West Nile Virus Envelope peptide |
West Nile Virus Envelope Antibody |
|
3441-002mg |
ProSci |
0.02 mg |
EUR 206.18 |
|
|
|
Description: West Nile Virus Envelope Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins. While the viral core protein is thought to contribute to the WNV-associated inflammation via apoptosis induced though the caspase-9 pathway, the highly glycosylated envelope protein plays a major role for WNV entry into target cells as this entry can be inhibited by using a recombinant domain III from the envelope glycoprotein. The WNV receptor has recently been identified as alpha v beta 3 integrin. |
West Nile Virus Envelope Antibody |
|
3441-01mg |
ProSci |
0.1 mg |
EUR 523.7 |
|
|
|
Description: West Nile Virus Envelope Antibody: West Nile Virus (WNV) is a member of the Flaviviridae, a plus-stranded virus family that includes St. Louis encephalitis virus, yellow fever virus, and Dengue virus. WNV was initially isolated in 1937 in the West Nile region of Uganda and has become prevalent in Africa, Asia, and Europe. It has rapidly spread across the United States with cases being observed in every continental state. Virus particles consist of a dense core made up of the core/capsid protein encapsulating the RNA genome surrounded by a membrane envelope embedded with envelope and matrix proteins. While the viral core protein is thought to contribute to the WNV-associated inflammation via apoptosis induced though the caspase-9 pathway, the highly glycosylated envelope protein plays a major role for WNV entry into target cells as this entry can be inhibited by using a recombinant domain III from the envelope glycoprotein. The WNV receptor has recently been identified as alpha v beta 3 integrin. |
West Nile Virus Envelope Peptide |
|
3441P |
ProSci |
0.05 mg |
EUR 197.7 |
|
Description: (IN) West Nile Virus Envelope peptide |
) West Nile virus protein (Horse) |
|
30-1261 |
Fitzgerald |
250 ug |
EUR 548.4 |
|
Description: Purified recombinant West Nile virus protein (Horse) |
 West Nile Virus Envelope Protein |
|
abx060680-100ug |
Abbexa |
100 ug |
EUR 794.4 |
|
|
 West Nile Envelope Virus Protein |
|
20-abx260322 |
Abbexa |
-
EUR 1062.00
-
EUR 410.40
-
EUR 1930.80
|
|
|
|
 Antibody) West Nile Virus (WNV) Antibody |
|
abx412023-01mg |
Abbexa |
0.1 mg |
EUR 610.8 |
|
|
 West Nile Virus NS1 protein |
|
80-1546 |
Fitzgerald |
100 ug |
EUR 541.2 |
|
Description: Purified Recombinant West Nile Virus NS1 protein (His tag) |
 West nile virus PCR kit |
|
PCR-VH054-48R |
Bioingentech |
50T |
EUR 987.6 |
The histological lesions related to an an infection with the Sars-CoV-2 are primarily noticed on the respiratory tract degree, however not solely. Analyses of those lesions strongly beneficied from autopsic research permitting us to enhance the information of the pathophysiology mechanisms of this rising infectious illness. Cytological analyses, notably these obtained from broncho-alveolar lavages, poorly contribute to the Covid-19 analysis, however might be usefull for eradicate a few differential diagnoses. Though non particular, the lesions noticed within the pulmonary parenchyma might be straight related to the presence of the Sars-CoV-2 due to ancillary instruments permitting its detection.
